Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab + methotrexate versus etanercept + methotrexate after inadequate response to adalimumab + methotrexate in rheumatoid arthritis
2012-001984-66Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of sarilumab in rheumatoid arthritis (RA) (2 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in DAS28-CRP. Started Mar 2013; status: completed.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-001984-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001984-66.